Prof. Jae Hun Shin

Principal Investigator

Jae Hun Shin

Ph.D.

Associate Professor, Bio-Convergence
Integrated Science & Engineering Division, Yonsei University

Assistant Professor Adjunct, Internal Medicine (Endocrinology), Yale University

Biography

Dr. Jae Hun Shin is an Associate Professor in the Integrated Science & Engineering Division at Yonsei University, where he leads the Tumor Immunology Lab. He also serves as an Adjunct Assistant Professor in the Section of Endocrinology, Internal Medicine at Yale University.

Dr. Shin received his Ph.D. in Immunobiology from Yale University and subsequently completed postdoctoral training there. His research focuses on a process called trogocytosis — the transfer of membrane fragments between cells — and how cancer cells exploit this mechanism to acquire immune regulatory molecules from T cells, thereby evading anti-tumor immunity.

His laboratory employs a multidisciplinary approach combining mass spectrometry, RNA sequencing, CRISPR/Cas9 screening, organoid models, and in vivo systems to identify immunotherapeutic targets and develop novel cancer immunotherapies including mRNA-LNP and CAR-T cell strategies.

Education

  • Ph.D. in Immunobiology

    Yale University

    2014

  • M.S. in Biotechnology

    Yonsei University

    2007

  • B.S. in Biotechnology

    Yonsei University

    2005

Positions

  • Associate Professor

    Bio-Convergence, Integrated Science & Engineering Division, Yonsei University

    2019 - Present

  • Assistant Professor Adjunct

    Section of Endocrinology, Internal Medicine, Yale University

    Current

  • Postdoctoral Associate

    Yale University

    2014 - 2019

  • Research Associate

    National Cancer Center, Korea

    2007 - 2009

Research Focus

  • Trogocytosis in Cancer Immune Evasion

    Investigating how cancer cells acquire immune regulatory molecules from T cells via trogocytosis to evade anti-tumor immunity.

  • Immunotherapeutic Target Identification

    Identifying novel targets for immunotherapy in metastatic cancers using mass spectrometry, RNA-seq, and CRISPR/Cas9 screening.

  • Therapeutic Development

    Developing next-generation cancer immunotherapies including mRNA-LNP and in vivo CAR-T approaches.